NLSP NLS Pharmaceutics Ltd.

2.55
+0.17  (+7%)
Previous Close 2.38
Open 2.44
52 Week Low 2.06
52 Week High 7.35
Market Cap $30,774,229
Shares 12,068,325
Float 4,348,325
Enterprise Value $33,730,784
Volume 53,635
Av. Daily Volume 596,061
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Quilience
Narcolepsy
Phase 2
Phase 2
Phase 2 clinical trial initiated, first patient enrolled September 14, 2021.
Nolazol
ADHD
Phase 2
Phase 2
Phase 2 trial has been completed.

Latest News

  1. STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the initiation of its Phase 2 clinical trial evaluating Quilience® (mazindol extended release or "ER") as a once-daily monotherapy for the treatment of excessive daytime sleepiness (EDS) and cataplexy, the primary symptoms of narcolepsy. The Company has begun enrolling patients and plans to conduct the trial in approximately 30 specialized centers across the U.S. and Europe.

    The trial is expected to enroll 60 patients with both…

    STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the initiation of its Phase 2 clinical trial evaluating Quilience® (mazindol extended release or "ER") as a once-daily monotherapy for the treatment of excessive daytime sleepiness (EDS) and cataplexy, the primary symptoms of narcolepsy. The Company has begun enrolling patients and plans to conduct the trial in approximately 30 specialized centers across the U.S. and Europe.

    The trial is expected to enroll 60 patients with both narcolepsy Type 1 and Type 2, who will receive treatment with either a 3mg dose of Quilience (mazindol ER) once daily for 28 days, or placebo. Patients in the trial will be randomized 1:1 into each treatment arm. The primary endpoint of the trial is the change from baseline in EDS as measured by the Epworth Sleepiness Scale (ESS), and a key secondary endpoint is the change from baseline in mean weekly number of cataplexy attacks in the anticipated subset of patients with cataplexy. Patients who complete the 4-week clinical study period will have the option to enroll in an open label extension (OLE) study, where each patient will be eligible to receive Quilience for an additional 6 months.

    "Initiating this clinical trial is an important milestone for NLS, and we remain focused on delivering top line results by year-end to demonstrate the potential benefits and safety profile of Quilience in the treatment of narcolepsy," said Alex Zwyer, Chief Executive Officer of NLS. "Quilience's unique mechanism of action, including its partial agonism of the orexin-2 receptor, has the potential to provide significant benefits to patients suffering from narcolepsy, which remains a major unmet medical need. I am thankful for all of the centers that are participating in this trial on behalf of their patients, and to our internal clinical and medical teams who have worked hard to move this trial along expediently as we seek to bring Quilience to the market as rapidly as possible."

    About NLS Pharmaceutics Ltd.

    NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating NolazolÒ (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

    Safe Harbor Statement

    This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the expected patient enrollment, clinical sites, dosing and primary endpoints of the clinical trial, the potential for trial patients to participate in an OLE study, the expected timing of the announcement of topline results and the potential benefits of Quilience. These forward-looking statements and their implications are based on the current expectations of the management of NLS only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS's products may not be approved by regulatory agencies, NLS's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS's process; NLS's products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS's patents may not be sufficient; NLS's products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov.

    Corporate Contact
    Alex Zwyer, CEO: +41 41 618 80 00

    Investor Relations Contact
    Cindy Rizzo: +1 908-229-7050
    www.nlspharma.com

    SOURCE: NLS Pharmaceutics Ltd.



    View source version on accesswire.com:
    https://www.accesswire.com/663930/NLS-Initiates-Phase-2-Trial-for-Quilience-in-Narcolepsy-and-Announces-First-Patient-Enrolled

    View Full Article Hide Full Article
  2. STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to

    present a corporate overview and participate in meetings with investors at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

    Presentation Details:

    H.C. Wainwright Virtual Presentation: Investors may listen to the NLS Pharmaceutics presentation online beginning on September 13th at 1:00pm CET / 7:00am ET via the following…

    STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to

    present a corporate overview and participate in meetings with investors at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

    Presentation Details:

    H.C. Wainwright Virtual Presentation: Investors may listen to the NLS Pharmaceutics presentation online beginning on September 13th at 1:00pm CET / 7:00am ET via the following link: https://journey.ct.events/view/40da20b0-3c77-4a22-9eac-9a6bb69b96cf. The presentation recording will be available for 90 days from the start of the conference. The H.C. Wainwright Global Investment Conference features six industry tracks including Healthcare & Biotechnology, as well as leading industry keynote speakers & presenting companies, investor meetings, and networking opportunities.

    About NLS Pharmaceutics Ltd.

    NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating NolazolÒ (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

    Corporate contact
    Alex Zwyer, CEO: +41 41 618 80 00

    Investor Relations contact
    Cindy Rizzo: +1 908-229-7050
    www.nlspharma.com

    SOURCE: NLS Pharmaceutics AG



    View source version on accesswire.com:
    https://www.accesswire.com/663070/NLS-Pharmaceutics-to-Participate-in-the-23rd-Annual-HC-Wainwright-Global-Investment-Conference

    View Full Article Hide Full Article
  3. STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for patent application No. 16/083,131. When the patent issues, it will cover oral formulations containing immediate-release and sustained-release layers of mazindol and their use in the treatment of attention deficit disorders (ADD or ADHD), related deficit of alertness or decline in vigilance, or excessive daytime sleepiness (e.g., narcolepsy…

    STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for patent application No. 16/083,131. When the patent issues, it will cover oral formulations containing immediate-release and sustained-release layers of mazindol and their use in the treatment of attention deficit disorders (ADD or ADHD), related deficit of alertness or decline in vigilance, or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia).

    A Notice of Allowance is issued after the USPTO makes a determination that a patent should be granted from an application. The patent, which is expected to be issued in the fourth quarter of 2021, will have a term that expires no earlier than March 2037. Based on its current clinical development plans to obtain regulatory approval, NLS would promptly list the patent in the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book if it receives market approval.

    "We are extremely pleased to have received this Notice of Allowance from the USPTO for our proprietary mazindol formulation as we advance the development of Quilience® (mazindol ER) to treat narcolepsy and potentially other sleep-wake disorders," said Alex Zwyer, Chief Executive Officer of NLS. "Earlier this year, we were granted similar patents in both the European Union and Canada, and we expect that the issuance of this patent will provide intellectual property protection for Quilience across the major markets in our business plan. Given our patent estate and the Orphan Drug Designations that we have in both the U.S. and Europe, we believe that our proprietary position on Quilience is strong."

    About NLS Pharmaceutics Ltd.

    NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating NolazolÒ (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

    Safe Harbor Statement

    This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the expected issuance date of the patent, that NLS expects to include the patent in the FDA's Orange Book, that it expects that the issuance of the patent will provide intellectual property protection in the major markets in its business plan and its belief that its proprietary position on Quilience is strong. These forward-looking statements and their implications are based on the current expectations of the management of NLS only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS's products may not be approved by regulatory agencies, NLS's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS's process; NLS's products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS's patents may not be sufficient; NLS's products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading 'Risk Factors' in NLS' annual report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov.

    Corporate Contact
    Alex Zwyer, CEO: +41 41 618 80 00

    Investor Relations Contact
    Cindy Rizzo: +1 908-229-7050
    www.nlspharma.com

    SOURCE: NLS Pharmaceutics AG



    View source version on accesswire.com:
    https://www.accesswire.com/660451/NLS-Pharmaceutics-Announces-Notice-of-Allowance-for-US-Patent-Application-Covering-its-Proprietary-Mazindol-Formulation

    View Full Article Hide Full Article
  4. STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021.

    Presentation Details:

    Date: Thursday, August 12, 2021
    Time: 10:00 AM ET

    The presentation will be webcast live and can be accessed by clicking this link, and will also be available for replay on Company's website at https://nls-pharma.com/

    About NLS Pharmaceutics Ltd.

    STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021.

    Presentation Details:

    Date: Thursday, August 12, 2021
    Time: 10:00 AM ET

    The presentation will be webcast live and can be accessed by clicking this link, and will also be available for replay on Company's website at https://nls-pharma.com/

    About NLS Pharmaceutics Ltd.

    NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating NolazolÒ (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

    Corporate contact

    Alex Zwyer, CEO: +41 41 618 80 00

    Investor Relations contact

    Cindy Rizzo: +1 908-229-7050

    www.nlspharma.com

    SOURCE: NLS Pharmaceutics AG



    View source version on accesswire.com:
    https://www.accesswire.com/658361/NLS-Pharmaceutics-to-Participate-in-the-Canaccord-Genuity-41st-Annual-Growth-Conference

    View Full Article Hide Full Article
  5. STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders, announces the appointment of Eric Konofal, M.D., Ph.D., as Chief Scientific Officer. Dr. Konofal is a co-founder and has over 30 years of experience as a physician and leading researcher in the field of sleep disorders and other CNS diseases.

    "As a co-founder of NLS, Eric has already made enormous contributions to the Company with regard to our early work on Quilience® and Nolazol®, and now he is able to fully devote his time and energy to advancing our drug pipeline…

    STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders, announces the appointment of Eric Konofal, M.D., Ph.D., as Chief Scientific Officer. Dr. Konofal is a co-founder and has over 30 years of experience as a physician and leading researcher in the field of sleep disorders and other CNS diseases.

    "As a co-founder of NLS, Eric has already made enormous contributions to the Company with regard to our early work on Quilience® and Nolazol®, and now he is able to fully devote his time and energy to advancing our drug pipeline and bringing value to patients, care givers, and our shareholders," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics. "The time for Eric to join us as our permanent Chief Scientific Officer couldn't be better as we recently submitted a series of patent applications, and our early-stage pipeline now includes five compounds in addition to Quilience® that have been issued patents or for which patent applications have been filed."

    "I am delighted to serve as the Company's Chief Scientific Officer where I can directly oversee the development of our pipeline of repurposed compounds and new chemical entities designed to address rare and complex CNS disorders," said Dr. Konofal. "Our lead product candidate, Quilience®, is an exciting technology that we discovered has partial orexin-2 binding activity, and therefore, offers potential to significantly improve the treatment of patients with narcolepsy. In addition to supporting this program, my focus will be on the advancement of our earlier-stage compounds intended to treat diseases such as myalgic encephalomyelitis/chronic fatigue syndrome (or ME/CFS) associated with COVID-19, Parkinson's disease, Alzheimer's disease, Huntington's disease, and other sleep-wake cycle disorders including Central Disorders of Hypersomnolence (CDH) such as Kleine-Levin Syndrome. I am very proud to have co-founded this Company, and I look forward to realizing its potential promise in helping patients with debilitating neurological conditions."

    Dr. Konofal is a primary clinical and internationally renowned scientific researcher, and is an accomplished drug hunter and drug pipeline developer. He is a senior medical consultant for the Pediatric Sleep Disorders Center at Robert-Debre University of Paris (APHP). Dr. Konofal served as Principal Clinical Investigator at the Clinical Pharmacology & Pharmacogenetic Department at Robert-Debre University of Paris. His research has focused on brain- and iron-dopamine interactions in subjects with neurological sleep disorders (RLS, PLMS), and ADHD. Additionally, Dr. Konofal served as a consultant at the sleep disorder center of Pitié-Salpêtrière University Hospital Group (APHP), specializing in ADHD, RLS, PLMS and CDH. He initiated previous studies based on iron and its role in the pathophysiology of ADHD, and has conducted extensive research on the relationship between the brain and iron.

    Dr. Konofal launched a clinical trial on the efficacy of mazindol in children with ADHD (clinicaltrials.gov identifier: NCT00508677) and obtained the U.S. patent for mazindol in the treatment of ADHD. He wrote the scientific rationale for Nolazol® and discovered the pharmacological profile of mazindol and its orexin-2 receptor binding properties.

    Dr. Konofal has authored over 70 peer-reviewed publications in the area of sleep disorders and other CNS diseases. His major scientific contributions are:

    • Pioneered the field Sleepiness in ADHD and increased motricity during sleep in ADHD (Lecendreux & Konofal, 2000; Konofal et al., 2001)
    • Discovered the primary role of iron in the brain in ADHD and its pathophysiology (Konofal et al. 2004; Patent Granted in 2006)
    • Discovered the effectiveness of mazindol in ADHD (2016) and the role of orexin-2 receptors in its binding profile

    Dr. Konofal earned his M.D. degree and Ph.D. at the University of Paris (APHP).

    About NLS Pharmaceutics Ltd.
    NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating NolazolÒ (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

    Safe Harbor Statement
    This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses its belief that the timing of the appointment as Chief Scientific Officer couldn't be better, the potential diseases that Dr. Konofal intends to focus on advancing of the Company's earlier stage compounds and that it looks forward to realizing its potential promise in helping patients with debilitating neurological conditions. These forward-looking statements and their implications are based on the current expectations of the management of NLS only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS's products may not be approved by regulatory agencies, NLS's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS's process; NLS's products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS's patents may not be sufficient; NLS's products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading 'Risk Factors' in NLS' annual report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov.

    Corporate Contact
    Alex Zwyer, CEO: +41 41 618 80 00

    Investor Relations Contact
    Cindy Rizzo: +1 908-229-7050
    www.nlspharma.com

    SOURCE: NLS Pharmaceutics AG



    View source version on accesswire.com:
    https://www.accesswire.com/655982/NLS-Pharmaceutics-Announces-the-Appointment-of-Eric-Konofal-MD-PhD-as-Chief-Scientific-Officer

    View Full Article Hide Full Article
View All NLS Pharmaceutics Ltd. News